Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$197.80|
|52 Week High||US$141.41|
|52 Week Low||US$210.10|
|1 Month Change||-2.95%|
|3 Month Change||5.22%|
|1 Year Change||22.61%|
|3 Year Change||115.80%|
|5 Year Change||277.77%|
|Change since IPO||537.86%|
Recent News & Updates
|ZTS||US Pharmaceuticals||US Market|
Return vs Industry: ZTS exceeded the US Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: ZTS underperformed the US Market which returned 32.8% over the past year.
Stable Share Price: ZTS is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: ZTS's weekly volatility (2%) has been stable over the past year.
About the Company
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms.
Zoetis Fundamentals Summary
|ZTS fundamental statistics|
Is ZTS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZTS income statement (TTM)|
|Cost of Revenue||US$2.24b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||4.03|
|Net Profit Margin||25.76%|
How did ZTS perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is Zoetis undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ZTS ($197.8) is trading above our estimate of fair value ($176.38)
Significantly Below Fair Value: ZTS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ZTS is poor value based on its PE Ratio (49.1x) compared to the US Pharmaceuticals industry average (22x).
PE vs Market: ZTS is poor value based on its PE Ratio (49.1x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: ZTS is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: ZTS is overvalued based on its PB Ratio (21.6x) compared to the US Pharmaceuticals industry average (3.3x).
How is Zoetis forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZTS's forecast earnings growth (11.4% per year) is above the savings rate (2%).
Earnings vs Market: ZTS's earnings (11.4% per year) are forecast to grow slower than the US market (15% per year).
High Growth Earnings: ZTS's earnings are forecast to grow, but not significantly.
Revenue vs Market: ZTS's revenue (7.3% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: ZTS's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZTS's Return on Equity is forecast to be very high in 3 years time (43.7%).
How has Zoetis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZTS has high quality earnings.
Growing Profit Margin: ZTS's current net profit margins (25.8%) are higher than last year (25.5%).
Past Earnings Growth Analysis
Earnings Trend: ZTS's earnings have grown by 19.6% per year over the past 5 years.
Accelerating Growth: ZTS's earnings growth over the past year (18.1%) is below its 5-year average (19.6% per year).
Earnings vs Industry: ZTS earnings growth over the past year (18.1%) exceeded the Pharmaceuticals industry 17.5%.
Return on Equity
High ROE: Whilst ZTS's Return on Equity (43.8%) is outstanding, this metric is skewed due to their high level of debt.
How is Zoetis's financial position?
Financial Position Analysis
Short Term Liabilities: ZTS's short term assets ($7.0B) exceed its short term liabilities ($2.1B).
Long Term Liabilities: ZTS's short term assets ($7.0B) do not cover its long term liabilities ($7.6B).
Debt to Equity History and Analysis
Debt Level: ZTS's debt to equity ratio (165.4%) is considered high.
Reducing Debt: ZTS's debt to equity ratio has reduced from 327.3% to 165.4% over the past 5 years.
Debt Coverage: ZTS's debt is well covered by operating cash flow (30%).
Interest Coverage: ZTS's interest payments on its debt are well covered by EBIT (11.8x coverage).
What is Zoetis's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ZTS's dividend (0.51%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.3%).
High Dividend: ZTS's dividend (0.51%) is low compared to the top 25% of dividend payers in the US market (3.57%).
Stability and Growth of Payments
Stable Dividend: ZTS is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: ZTS is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: ZTS is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZTS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kristin Peck (50 yo)
Ms. Kristin C. Peck serves as Chief Executive Officer of Zoetis Inc. since January 01, 2020 and serves as its Director since October 3, 2019. Ms. Peck served as Group President of U.S. Operations, Business...
CEO Compensation Analysis
Compensation vs Market: Kristin's total compensation ($USD10.37M) is about average for companies of similar size in the US market ($USD11.29M).
Compensation vs Earnings: Kristin's compensation has increased by more than 20% in the past year.
Experienced Management: ZTS's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: ZTS's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ZTS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Zoetis Inc.'s employee growth, exchange listings and data sources
- Name: Zoetis Inc.
- Ticker: ZTS
- Exchange: NYSE
- Founded: 1952
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$93.746b
- Shares outstanding: 473.94m
- Website: https://www.zoetis.com
Number of Employees
- Zoetis Inc.
- 10 Sylvan Way
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 23:05|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.